280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

On December 1, 2023 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, reported that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling (Press release, 280Bio, DEC 1, 2023, View Source [SID1234638097]). 280Bio is a wholly owned subsidiary of Shanghai Yingli Pharmaceuticals, Inc. (Yingli Pharma) of Shanghai, China. KRAS, NRAS and HRAS genes are frequently mutated in many tumor indications causally associated with promoting tumor cell growth. TEB-17231 demonstrated potent inhibition of tumor cell proliferation in vitro and in vivo in preclinical research, exhibiting activity with different KRAS, NRAS and HRAS alterations, including tumors that have become resistant to KRAS G12C inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are gratified that the first patient has been dosed with our novel pan-RAS inhibitor, marking a major step in TEB-17231’s clinical development, and introducing new medicines for the patients we hope to serve." said Michael Hui, Chief Executive Officer of 280Bio Inc., "This milestone highlights our commitment to addressing unmet needs in cancers through precision oncology approaches. We look forward to continued enrollment and dosing of patients in this trial."

This first US patient was enrolled at The University of Texas MD Anderson Cancer Center, Houston, Texas, by David Hong, MD, Deputy Chair of Investigational Cancer Therapeutics and lead investigator on the trial.

Reflecting on the high unmet need for new cancer agents, Dr. Zusheng Xu, Head of Research and Development of Yingli Pharma, said "TEB-17231 was developed to have a broader activity against the oncogenic RAS signaling pathways, than is currently demonstrated for many of the KRAS inhibitors. With its excellent pharmacologic and in vivo anti-tumor properties, we are hopeful that TEB-17231 will also be determined to be safe and efficacious by continuous oral dosing in patients."